NEW YORK (GenomeWeb) – After releasing white papers, holding several public workshops, and listening to stakeholder feedback, the US Food and Drug Administration has released two draft guidances outlining how it might review the analytical and clinical validity of next-generation sequencing tests.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.